Business overview

About us

TISSUE REGENIX GROUP is a pioneering, international medical technology company, focusing on the development of regenerative products utilising our two platform technologies, dCELL^®, addressing soft tissue needs, and BioRinse^TM, providing sterile bone allografts.

We are currently helping to transform the treatment of patients in key surgical applications: BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology, and Cardiac.

Our Vision

To establish TRG as a leader in the science and innovation of regenerative medicine.

Transforming patient care and delivering favourable health economic outcomes.

Group snapshot: progress in 2021

$19.7m revenue FY2021
$7.7m cash at 31 December 2021
Distribution via strategic partners, direct specialist sales and distribution partners

Product portfolio

High growth product lines focused on bone, skin (dermis) and birth tissue:

Bone

BioRinse®

Flagship Products

ConCelltrate®

Applications

Spine
Foot/ankle
Dental
Orthopaedics

Differentiators

Induces new bone growth
Faster healing
Superior handling
Reduced flush out

Soft Tissue

dCELL®

Flagship Products

DermaPure®

Applications

Urogynaecology
Sports medicine
Open wound
Plastics

Differentiators

Clinical outcomes
No second graft site required
Stored at room temperature
Superior handling

Birth Tissue

Proprietary

Flagship Products

AmnioWorks™

Applications

Ophthalmology
Wound covering

Differentiators

Clinical outcomes
Barrier can provide faster healing
Stored at room temperature

Global Operations Infrastructure

Platform for international expansion

Current locations

Tissue Regenix, Leeds, UK

Cellright Technologies, San Antonio, Texas

GBM-V, Rostock, Germany

locations map

Our values

Dedication to patients

Passion for innovation

Drive for excellence

Uncompromising integrity

You may also be interested in